NASDAQ:CUR - Neuralstem Stock Price, Price Target & More

$1.66 +0.04 (+2.47 %)
(As of 04/26/2018 03:52 AM ET)
Previous Close$1.66
Today's Range$1.5901 - $1.66
52-Week Range$0.88 - $6.60
Volume28,150 shs
Average Volume237,444 shs
Market Capitalization$24.71 million
P/E RatioN/A
Dividend YieldN/A
Beta1.51

About Neuralstem (NASDAQ:CUR)

Neuralstem logoNeuralstem, Inc., a clinical stage biopharmaceutical company, focuses on the research and development of nervous system therapies based on its proprietary human neuronal stem cells and small molecule compounds. The company's stem cell based technology enables the isolation and expansion of human neural stem cells from various areas of the developing human brain and spinal cord enabling the generation of physiologically relevant human neurons of various types. It is developing products include NSI-189, a chemical entity, which is in Phase II clinical trial for the treatment of major depressive disorder, as well as is in preclinical programs for the MCAO stroke, type 1 and 2 diabetes related neuropathy, irradiation-induced cognition, long-term potentiation enhancement, and angelman syndrome. The company is also developing NSI-566, which has completed Phase II clinical trial for treating amyotrophic lateral sclerosis disease, as well as is in Phase I clinical trials for the treatment of chronic spinal cord injury and motor deficits due to ischemic stroke. Neuralstem, Inc. was founded in 1996 and is headquartered in Germantown, Maryland.

Receive CUR News and Ratings via Email

Sign-up to receive the latest news and ratings for CUR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CUR
CUSIPN/A
Phone301-366-4841

Debt

Debt-to-Equity RatioN/A
Current Ratio8.24%
Quick Ratio8.24%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$260,000.00
Price / Sales96.79
Cash FlowN/A
Price / CashN/A
Book Value$0.56 per share
Price / Book2.96

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-15,660,000.00
Net Margins-8,075.26%
Return on Equity-137.90%
Return on Assets-83.33%

Miscellaneous

Employees6
Outstanding Shares15,160,000

How to Become a New Pot Stock Millionaire

Neuralstem (NASDAQ:CUR) Frequently Asked Questions

What is Neuralstem's stock symbol?

Neuralstem trades on the NASDAQ under the ticker symbol "CUR."

How were Neuralstem's earnings last quarter?

Neuralstem, Inc. (NASDAQ:CUR) released its quarterly earnings results on Monday, April, 2nd. The company reported ($0.20) EPS for the quarter. The business earned $0.19 million during the quarter. Neuralstem had a negative net margin of 8,075.26% and a negative return on equity of 137.90%. View Neuralstem's Earnings History.

What price target have analysts set for CUR?

0 brokers have issued twelve-month target prices for Neuralstem's shares. Their forecasts range from $1.91 to $1.91. On average, they expect Neuralstem's share price to reach $1.91 in the next year. View Analyst Ratings for Neuralstem.

Who are some of Neuralstem's key competitors?

Who are Neuralstem's key executives?

Neuralstem's management team includes the folowing people:
  • Mr. Richard J. Daly, Chairman, CEO, Pres and Interim Principal Financial & Accounting Officer (Age 57)
  • Dr. Karl Y. Johe Ph.D., Co-Founder & Chief Scientific Officer (Age 58)
  • Danielle Spangler, Director of Investor Relations
  • Dr. Thomas G. Hazel Ph.D., Sr. VP of Research
  • Dr. David P. Recker, Chief Medical Officer (Age 60)

Has Neuralstem been receiving favorable news coverage?

Headlines about CUR stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group scores the sentiment of media coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Neuralstem earned a media sentiment score of 0.25 on Accern's scale. They also gave headlines about the company an impact score of 46.31 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of Neuralstem?

Shares of CUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Neuralstem's stock price today?

One share of CUR stock can currently be purchased for approximately $1.66.

How big of a company is Neuralstem?

Neuralstem has a market capitalization of $24.71 million and generates $260,000.00 in revenue each year. Neuralstem employs 6 workers across the globe.

How can I contact Neuralstem?

Neuralstem's mailing address is 20271 Goldenrod Lane, Germantown MD, 20876. The company can be reached via phone at 301-366-4841 or via email at [email protected]


MarketBeat Community Rating for Neuralstem (CUR)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  181 (Vote Outperform)
Underperform Votes:  135 (Vote Underperform)
Total Votes:  316
MarketBeat's community ratings are surveys of what our community members think about Neuralstem and other stocks. Vote "Outperform" if you believe CUR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CUR will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Neuralstem (NASDAQ:CUR) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: N/AN/AN/ABuy
Consensus Rating Score: N/AN/AN/A3.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $1.91$1.91$1.91$2.19
Price Target Upside: 15.06% upside0.00% downside0.00% downside31.13% downside

Neuralstem (NASDAQ:CUR) Consensus Price Target History

Price Target History for Neuralstem (NASDAQ:CUR)

Neuralstem (NASDAQ:CUR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/11/2018S&P Equity ResearchLower Price Target$2.26 -> $1.91LowView Rating Details
11/10/2016Roth CapitalReiterated RatingBuy$1.20N/AView Rating Details
11/7/2016AegisInitiated CoverageBuyN/AView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$4.00N/AView Rating Details
(Data available from 4/26/2016 forward)

Earnings

Neuralstem (NASDAQ:CUR) Earnings History and Estimates Chart

Earnings by Quarter for Neuralstem (NASDAQ:CUR)

Neuralstem (NASDAQ CUR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/2/2018Q4 2017($0.20)$0.19 millionViewN/AView Earnings Details
11/13/2017Q3 2017($0.18)ViewN/AView Earnings Details
8/8/2017Q2 2017($9.49)($0.39)ViewN/AView Earnings Details
5/10/2017Q1 2017($0.43)ViewN/AView Earnings Details
11/8/2016Q3($0.03)($0.05)ViewN/AView Earnings Details
8/11/2016Q2($0.05)($0.04)$2.50 million$2.50 millionViewN/AView Earnings Details
5/9/2016Q1($0.06)($0.07)ViewN/AView Earnings Details
3/14/2016Q4($0.07)($0.05)ViewN/AView Earnings Details
11/9/2015Q315($0.07)($0.06)ViewN/AView Earnings Details
8/10/2015Q2($0.06)($0.06)ViewN/AView Earnings Details
5/8/2015Q115($0.07)($0.06)$2.92 millionViewN/AView Earnings Details
4/20/2015($0.07)($0.06)ViewN/AView Earnings Details
3/16/2015Q4 2014($0.05)($0.06)$0.01 millionViewN/AView Earnings Details
11/7/2014Q314($0.05)($0.05)$0.01 millionViewN/AView Earnings Details
8/8/2014Q214($0.05)($0.08)$0.10 million$0.01 millionViewN/AView Earnings Details
5/12/2014Q114($0.05)($0.04)$0.35 million$0.0042 millionViewN/AView Earnings Details
3/10/2014Q4 2013($0.06)($0.04)ViewN/AView Earnings Details
11/11/2013Q3($0.04)($0.09)ViewN/AView Earnings Details
8/9/2013Q213($0.05)($0.09)$0.0781 million$0.0025 millionViewN/AView Earnings Details
5/10/2013Q1 2013($0.52)($0.52)$0.10 million$0.10 millionViewN/AView Earnings Details
3/15/2013Q4 2012($0.52)($0.39)ViewN/AView Earnings Details
11/9/2012Q312($0.04)($0.04)ViewN/AView Earnings Details
8/10/2012Q2 2012($0.78)($0.57)ViewN/AView Earnings Details
5/9/2012Q1 2012($0.62)ViewN/AView Earnings Details
3/29/2012Q4 2011($0.78)($0.68)ViewN/AView Earnings Details
11/9/2011Q3 2011($0.91)($0.86)ViewN/AView Earnings Details
8/10/2011Q2 2011($0.99)ViewN/AView Earnings Details
5/10/2011Q1 2011($1.30)($0.96)ViewN/AView Earnings Details
3/16/2011Q4 2010($1.30)($0.65)ViewN/AView Earnings Details
11/16/2010Q3 2010($1.43)($1.16)ViewN/AView Earnings Details
8/16/2010Q2 2010($1.40)ViewN/AView Earnings Details
5/17/2010Q1 2010($1.27)ViewN/AView Earnings Details
3/31/2010Q4 2009($1.04)ViewN/AView Earnings Details
11/17/2009Q3 2009($1.91)ViewN/AView Earnings Details
8/13/2009Q2 2009($1.05)ViewN/AView Earnings Details
5/15/2009Q1 2009($1.07)ViewN/AView Earnings Details
3/31/2009Q4 2008($1.43)ViewN/AView Earnings Details
11/13/2008Q3 2008($1.29)ViewN/AView Earnings Details
8/14/2008Q2 2008($1.20)ViewN/AView Earnings Details
5/15/2008Q1 2008($0.94)ViewN/AView Earnings Details
3/28/2008Q4 2007($1.17)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Neuralstem (NASDAQ:CUR) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Neuralstem (NASDAQ CUR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 15.43%
Institutional Ownership Percentage: 7.03%
Insider Trading History for Neuralstem (NASDAQ:CUR)
Institutional Ownership by Quarter for Neuralstem (NASDAQ:CUR)

Neuralstem (NASDAQ CUR) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/17/2017Richard J DalyCEOBuy7,500$4.00$30,000.0023,312View SEC Filing  
3/24/2017Jones Jonathan Brian LloydCFOBuy5,455$5.50$30,002.507,859View SEC Filing  
2/24/2017Richard J DalyCEOBuy2,591$3.86$10,001.2615,812View SEC Filing  
1/25/2017Richard J DalyCEOBuy2,841$3.52$10,000.3213,221View SEC Filing  
12/23/2016Richard J DalyCEOBuy32,259$0.31$10,000.29134,939View SEC Filing  
11/25/2016Richard J DalyCEOBuy35,715$0.28$10,000.20102,680View SEC Filing  
10/25/2016Richard J DalyCEOBuy35,715$0.28$10,000.2066,965View SEC Filing  
9/23/2016Richard J DalyCEOBuy31,250$0.32$10,000.0031,250View SEC Filing  
11/16/2015Karl JoheInsiderSell25,000$1.09$27,250.00826,304View SEC Filing  
11/9/2015Karl JoheInsiderSell25,000$1.18$29,500.00851,304View SEC Filing  
11/2/2015Karl JoheInsiderSell25,000$1.17$29,250.00876,304View SEC Filing  
10/26/2015Karl JoheInsiderSell25,000$1.13$28,250.00901,304View SEC Filing  
10/19/2015Karl JoheInsiderSell25,000$1.23$30,750.00926,304View SEC Filing  
10/12/2015Karl JoheInsiderSell25,000$1.31$32,750.00951,304View SEC Filing  
10/5/2015Karl JoheInsiderSell25,000$1.26$31,500.00976,304View SEC Filing  
9/28/2015Karl JoheInsiderSell25,000$1.64$41,000.001,001,304View SEC Filing  
9/21/2015Karl JoheInsiderSell25,000$1.52$38,000.001,026,304View SEC Filing  
9/2/2014Karl JoheInsiderSell6,000$4.09$24,540.00View SEC Filing  
8/1/2014Karl JoheInsiderSell6,000$2.78$16,680.00View SEC Filing  
7/1/2014Karl JoheInsiderSell6,000$4.17$25,020.00View SEC Filing  
6/2/2014Karl JoheInsiderSell6,000$4.25$25,500.00View SEC Filing  
5/5/2014William Clyde OldakerDirectorBuy15,235$3.50$53,322.50View SEC Filing  
4/22/2014Richard GarrCEOSell7,000$4.25$29,750.00View SEC Filing  
4/1/2014Karl JoheInsiderSell6,000$4.11$24,660.00View SEC Filing  
3/20/2014Karl JoheInsiderSell6,000$4.04$24,240.00View SEC Filing  
10/18/2013Karl JoheInsiderSell10,000$2.44$24,400.00View SEC Filing  
9/20/2013Karl JoheInsiderSell10,000$2.62$26,200.00View SEC Filing  
9/19/2013Karl JoheInsiderSell10,000$2.61$26,100.00View SEC Filing  
8/20/2013Karl JoheInsiderSell20,000$1.55$31,000.00View SEC Filing  
7/22/2013Karl JoheInsiderSell12,800$1.62$20,736.00View SEC Filing  
6/20/2013Karl JoheInsiderSell12,800$1.40$17,920.00View SEC Filing  
6/7/2013Richard GarrCEOSell6,000$1.42$8,520.00View SEC Filing  
5/20/2013Karl JoheInsiderSell12,800$1.51$19,328.00View SEC Filing  
2/25/2013Richard GarrCEOSell12,000$1.15$13,800.00View SEC Filing  
11/20/2012Karl JoheInsiderSell12,800$1.00$12,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Neuralstem (NASDAQ CUR) News Headlines

Source:
DateHeadline
Neuralstem (CUR) Presents At ARMs 6th Cell & Gene Therapy Investor Day - SlideshowNeuralstem (CUR) Presents At ARM's 6th Cell & Gene Therapy Investor Day - Slideshow
seekingalpha.com - April 20 at 8:33 AM
International Stem Cell Corporation to Present Interim Clinical Results at the American Academy of NeurologyInternational Stem Cell Corporation to Present Interim Clinical Results at the American Academy of Neurology
globenewswire.com - April 18 at 8:53 AM
Blog Exposure - Idera Pharma Announces Clinical Development Support Agreement with Pillar Partners FoundationBlog Exposure - Idera Pharma Announces Clinical Development Support Agreement with Pillar Partners Foundation
finance.yahoo.com - April 18 at 8:53 AM
Neuralstem (CUR) Downgraded by ValuEngineNeuralstem (CUR) Downgraded by ValuEngine
www.americanbankingnews.com - April 16 at 12:18 AM
Neuralstem to Present Clinical Update at the Alliance for Regenerative Medicine 6th Annual Cell & Gene Therapy ...Neuralstem to Present Clinical Update at the Alliance for Regenerative Medicine 6th Annual Cell & Gene Therapy ...
www.nasdaq.com - April 11 at 8:50 AM
Neuralstem up 22% premarket on advancement of NSI-566Neuralstem up 22% premarket on advancement of NSI-566
seekingalpha.com - April 11 at 8:50 AM
Today’s Research Reports on Trending Tickers: Neuralstem and ImmunomedicsToday’s Research Reports on Trending Tickers: Neuralstem and Immunomedics
finance.yahoo.com - April 11 at 8:50 AM
Neuralstem Announces First Surgery Completed in Cervical Cohort of Phase 1 Clinical Trial in Patients with Chronic ...Neuralstem Announces First Surgery Completed in Cervical Cohort of Phase 1 Clinical Trial in Patients with Chronic ...
globenewswire.com - April 10 at 5:17 PM
Neuralstem Reports Year End 2017 Fiscal Results and Business UpdateNeuralstem Reports Year End 2017 Fiscal Results and Business Update
globenewswire.com - April 2 at 9:25 AM
AIT Therapeutics (AITB) vs. Neuralstem (CUR) Financial ContrastAIT Therapeutics (AITB) vs. Neuralstem (CUR) Financial Contrast
www.americanbankingnews.com - March 18 at 1:23 PM
Neuralstem Announces Publication of a Study in Nature Medicine Showing Benefits of NSI-566 in a Primate Model of Spinal Cord InjuryNeuralstem Announces Publication of a Study in Nature Medicine Showing Benefits of NSI-566 in a Primate Model of Spinal Cord Injury
finance.yahoo.com - March 14 at 11:41 AM
Neuralstem (CUR) to Release Quarterly Earnings on WednesdayNeuralstem (CUR) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - March 14 at 1:35 AM
Neuralstem (CUR) Reports Publication of Study in Nature Medicine Showing Benefits of NSI-566 in Primate Model of ... - StreetInsider.comNeuralstem (CUR) Reports Publication of Study in Nature Medicine Showing Benefits of NSI-566 in Primate Model of ... - StreetInsider.com
www.streetinsider.com - March 13 at 5:32 PM
Neuralstem to Participate at Upcoming Investor Conferences - GlobeNewswire (press release)Neuralstem to Participate at Upcoming Investor Conferences - GlobeNewswire (press release)
globenewswire.com - March 13 at 5:32 PM
Neuralstem Announces Publication of a Study in Nature Medicine Showing Benefits of NSI-566 in a Primate Model of Spinal Cord Injury Neuralstem Announces Publication of a Study in Nature Medicine Showing Benefits of NSI-566 in a Primate Model of Spinal Cord Injury 
finance.yahoo.com - March 13 at 10:04 AM
Neuralstem to Participate at Upcoming Investor ConferencesNeuralstem to Participate at Upcoming Investor Conferences
finance.yahoo.com - March 12 at 5:17 PM
Neuralstem (CUR) and Theravance Biopharma (TBPH) Head to Head ComparisonNeuralstem (CUR) and Theravance Biopharma (TBPH) Head to Head Comparison
www.americanbankingnews.com - March 2 at 11:22 PM
Biotech Stocks Research Reports Released on OvaScience, Pacific ... - PR Newswire (press release)Biotech Stocks' Research Reports Released on OvaScience, Pacific ... - PR Newswire (press release)
www.prnewswire.com - February 14 at 3:31 PM
Neuralstem to Participate at The Young Jewish Professionals CEO ... - GlobeNewswire (press release)Neuralstem to Participate at The Young Jewish Professionals CEO ... - GlobeNewswire (press release)
globenewswire.com - February 8 at 3:27 PM
Neuralstem to Participate at The Young Jewish Professionals CEO Healthcare SymposiumNeuralstem to Participate at The Young Jewish Professionals CEO Healthcare Symposium
feeds.benzinga.com - February 8 at 7:45 AM
Neuralstem - Burning Cash, Looking For Answers - Seeking AlphaNeuralstem - Burning Cash, Looking For Answers - Seeking Alpha
seekingalpha.com - February 8 at 6:53 AM
Financial Review: Innocoll (INNL) versus Neuralstem (CUR)Financial Review: Innocoll (INNL) versus Neuralstem (CUR)
www.americanbankingnews.com - January 30 at 3:18 PM
Neuralstem to Participate at Cell and Gene Therapy World - GlobeNewswire (press release)Neuralstem to Participate at Cell and Gene Therapy World - GlobeNewswire (press release)
globenewswire.com - January 22 at 8:25 AM
Neuralstem (CUR) Price Target Cut to $1.91 by Analysts at S&P Equity ResearchNeuralstem (CUR) Price Target Cut to $1.91 by Analysts at S&P Equity Research
www.americanbankingnews.com - January 11 at 4:08 PM
Neuralstem to Present at The Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and Technology - GlobeNewswire (press release)Neuralstem to Present at The Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and Technology - GlobeNewswire (press release)
globenewswire.com - January 7 at 10:44 PM
Neuralstem to Present at The Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and TechnologyNeuralstem to Present at The Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and Technology
finance.yahoo.com - January 6 at 9:32 AM
Neuralstem to Present at The Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and TechnologyNeuralstem to Present at The Neuroscience Innovation Forum for BD&L and Investment in Therapeutics and Technology
feeds.benzinga.com - January 5 at 6:50 PM
Neuralstem, Inc. (CUR) Sees Significant Increase in Short InterestNeuralstem, Inc. (CUR) Sees Significant Increase in Short Interest
www.americanbankingnews.com - December 31 at 4:22 AM
Financial Review: Neuralstem (CUR) vs. Emergent Biosolutions (EBS)Financial Review: Neuralstem (CUR) vs. Emergent Biosolutions (EBS)
www.americanbankingnews.com - December 30 at 9:12 AM
ETFs with exposure to Neuralstem, Inc. : December 26, 2017ETFs with exposure to Neuralstem, Inc. : December 26, 2017
finance.yahoo.com - December 28 at 1:37 PM
Neuralstem (CUR) Appoints Xi Chen PhD to BoardNeuralstem (CUR) Appoints Xi Chen PhD to Board
www.streetinsider.com - December 20 at 9:32 AM
Today’s Research Reports on Trending Tickers: Geron Corporation and Neuralstem, Inc.Today’s Research Reports on Trending Tickers: Geron Corporation and Neuralstem, Inc.
finance.yahoo.com - December 8 at 9:31 AM
ETFs with exposure to Neuralstem, Inc. : December 7, 2017ETFs with exposure to Neuralstem, Inc. : December 7, 2017
finance.yahoo.com - December 7 at 5:44 PM
Neuralstem Inc. (CUR) Surged To A 4-Month High On Study ResultsNeuralstem Inc. (CUR) Surged To A 4-Month High On Study Results
www.rttnews.com - December 6 at 9:40 AM
800%+ Revenue Growth Could Imply 200-300% Returns for This Small Cap Stock800%+ Revenue Growth Could Imply 200-300% Returns for This Small Cap Stock
finance.yahoo.com - December 6 at 9:40 AM
Neuralstem (CUR) Announces Positive Updated Data from Phase 2 Study of NSI-189 in Major Depressive DisorderNeuralstem (CUR) Announces Positive Updated Data from Phase 2 Study of NSI-189 in Major Depressive Disorder
www.streetinsider.com - December 5 at 5:15 PM
Neuralstem, Inc. (CUR): Updated Phase II Trial Success in Major Depressive Disorder Takes the Street by StormNeuralstem, Inc. (CUR): Updated Phase II Trial Success in Major Depressive Disorder Takes the Street by Storm
finance.yahoo.com - December 5 at 5:15 PM
Does Neuralstem Inc’s (CUR) Past Performance Indicate A Stronger Future?Does Neuralstem Inc’s (CUR) Past Performance Indicate A Stronger Future?
finance.yahoo.com - November 30 at 5:14 PM
Contrasting Neuralstem (CUR) and The CompetitionContrasting Neuralstem (CUR) and The Competition
www.americanbankingnews.com - November 18 at 11:14 AM
Neuralstem (CUR) Reports Presentation of Clinical Data for NSI-189 in Major Depressive Disorder at at ACNP MeetingNeuralstem (CUR) Reports Presentation of Clinical Data for NSI-189 in Major Depressive Disorder at at ACNP Meeting
www.streetinsider.com - November 17 at 1:37 PM
Neuralstem Announces Presentation of Clinical Data for NSI-189 in Major Depressive Disorder at the Upcoming American College of Neuropsychopharmacology Annual MeetingNeuralstem Announces Presentation of Clinical Data for NSI-189 in Major Depressive Disorder at the Upcoming American College of Neuropsychopharmacology Annual Meeting
finance.yahoo.com - November 16 at 6:17 PM
Comparing Sophiris Bio (SPHS) & Neuralstem (CUR)Comparing Sophiris Bio (SPHS) & Neuralstem (CUR)
www.americanbankingnews.com - November 14 at 5:18 AM
Neuralstem Reports Third Quarter 2017 Fiscal Results and Provides Clinical and Business Update - GlobeNewswire (press release)Neuralstem Reports Third Quarter 2017 Fiscal Results and Provides Clinical and Business Update - GlobeNewswire (press release)
globenewswire.com - November 13 at 9:13 PM
Neuralstem Reports Third Quarter 2017 Fiscal Results and Provides Clinical and Business UpdateNeuralstem Reports Third Quarter 2017 Fiscal Results and Provides Clinical and Business Update
finance.yahoo.com - November 13 at 12:41 PM
Neuralstem reports 3Q lossNeuralstem reports 3Q loss
finance.yahoo.com - November 13 at 12:41 PM
ETFs with exposure to Neuralstem, Inc. : November 10, 2017ETFs with exposure to Neuralstem, Inc. : November 10, 2017
finance.yahoo.com - November 10 at 5:35 PM
Neuralstem (CUR) Names Dr. David Recker as Chief Medical Officer - StreetInsider.comNeuralstem (CUR) Names Dr. David Recker as Chief Medical Officer - StreetInsider.com
www.streetinsider.com - November 10 at 7:26 AM
Neuralstem, Inc. :CUR-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017Neuralstem, Inc. :CUR-US: Earnings Analysis: Q3, 2017 By the Numbers : November 9, 2017
finance.yahoo.com - November 10 at 7:26 AM
Neuralstem Strengthens Executive Leadership Team with Appointment of Dr. David Recker as Chief Medical OfficerNeuralstem Strengthens Executive Leadership Team with Appointment of Dr. David Recker as Chief Medical Officer
finance.yahoo.com - November 9 at 12:11 AM
Neuralstem, Inc. (CUR) Scheduled to Post Earnings on MondayNeuralstem, Inc. (CUR) Scheduled to Post Earnings on Monday
www.americanbankingnews.com - October 30 at 10:22 AM

SEC Filings

Neuralstem (NASDAQ:CUR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Neuralstem (NASDAQ:CUR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Neuralstem (NASDAQ CUR) Stock Chart for Thursday, April, 26, 2018

Loading chart…

This page was last updated on 4/26/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.